Post Approval Study of the Eversense® Continuous Glucose Monitoring

NACompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DEVICE

Eversense® CGM System

Continuous Glucose monitoring device

Trial Locations (17)

12206

Albany Medical College, Albany

19053

Diabetes & Endocrinology Consultants of Pennsylvania, LLC, Feasterville

21204

MODEL Clinical research, Baltimore

27834

Physicians East, Greenville

28401

PMG Research of Wilmington, LLC, Wilmington

30318

Atlanta Diabetes Associates, Atlanta

33312

The Center for Diabetes and Endocrine Care, Fort Lauderdale

38133

AM Diabetes & Endocrinology, Bartlett

48126

Metro Detroit Endocrinology Center, Dearborn

63017

Diabetes and Endocrinology Specialists, Inc., Chesterfield

77095

Javara, Inc, Houston

77433

Clinical Research Solution, LLC, Cypress

78229

Diabetes and Glandular Disease Clinic, San Antonio

78231

Consano Clinical Research, LLC, Shavano Park

78731

Texas Diabetes and Endocrinology, Austin

80113

Denver Endocrinology, Diabetes & Thyroid Center, Englewood

92663

Hoag Memorial Hospital Presbyterian/Mary Dick Allen Diabetes Center, Newport Beach

All Listed Sponsors
lead

Senseonics, Inc.

INDUSTRY

NCT03908125 - Post Approval Study of the Eversense® Continuous Glucose Monitoring | Biotech Hunter | Biotech Hunter